2/8
02:04 am
cgem
Cullinan Therapeutics (NASDAQ:CGEM) was downgraded by analysts at
Wall S
Neutral
Report
Cullinan Therapeutics (NASDAQ:CGEM) was downgraded by analysts at
Wall S
2/5
07:00 am
cgem
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
Medium
Report
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
2/4
06:43 am
cgem
Cullinan Therapeutics (NASDAQ:CGEM) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Medium
Report
Cullinan Therapeutics (NASDAQ:CGEM) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
2/1
08:16 pm
cgem
Cullinan Therapeutics (NASDAQ:CGEM) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Medium
Report
Cullinan Therapeutics (NASDAQ:CGEM) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
1/31
01:33 am
cgem
Cullinan Therapeutics (NASDAQ:CGEM) was upgraded by analysts at
Wall Str
Medium
Report
Cullinan Therapeutics (NASDAQ:CGEM) was upgraded by analysts at
Wall Str
1/24
12:30 am
cgem
Cullinan Therapeutics (NASDAQ:CGEM) was downgraded by analysts at
Wall S
Medium
Report
Cullinan Therapeutics (NASDAQ:CGEM) was downgraded by analysts at
Wall S
1/23
06:57 am
cgem
Cullinan Therapeutics (NASDAQ:CGEM) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Cullinan Therapeutics (NASDAQ:CGEM) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/8
10:57 am
cgem
Cullinan Therapeutics (NASDAQ:CGEM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Cullinan Therapeutics (NASDAQ:CGEM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/8
08:02 am
cgem
Cullinan Therapeutics (NASDAQ:CGEM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Cullinan Therapeutics (NASDAQ:CGEM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
1/8
07:00 am
cgem
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
Medium
Report
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
12/9
08:19 am
cgem
Cullinan Therapeutics (NASDAQ:CGEM) had its price target raised by analysts at Wedbush from $25.00 to $34.00. They now have an "outperform" rating on the stock.
Low
Report
Cullinan Therapeutics (NASDAQ:CGEM) had its price target raised by analysts at Wedbush from $25.00 to $34.00. They now have an "outperform" rating on the stock.
12/8
10:31 am
cgem
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
High
Report
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
12/2
03:41 pm
cgem
Cullinan Therapeutics (NASDAQ:CGEM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Cullinan Therapeutics (NASDAQ:CGEM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/1
07:00 am
cgem
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Medium
Report
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
11/24
12:08 pm
cgem
Cullinan Therapeutics (NASDAQ:CGEM) had its "buy" rating reaffirmed by analysts at BTIG Research.
High
Report
Cullinan Therapeutics (NASDAQ:CGEM) had its "buy" rating reaffirmed by analysts at BTIG Research.
11/22
02:11 am
cgem
Cullinan Therapeutics (NASDAQ:CGEM) was upgraded by analysts at
Wall Str
High
Report
Cullinan Therapeutics (NASDAQ:CGEM) was upgraded by analysts at
Wall Str
11/20
11:08 pm
cgem
Cullinan Therapeutics (NASDAQ:CGEM) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
Medium
Report
Cullinan Therapeutics (NASDAQ:CGEM) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
11/20
02:10 pm
cgem
Cullinan Therapeutics (NASDAQ:CGEM) was given a new $26.00 price target on by analysts at New Street Research.
Low
Report
Cullinan Therapeutics (NASDAQ:CGEM) was given a new $26.00 price target on by analysts at New Street Research.
11/20
11:04 am
cgem
Cullinan Therapeutics (NASDAQ:CGEM) had its price target raised by analysts at HC Wainwright from $24.00 to $26.00. They now have a "buy" rating on the stock.
Medium
Report
Cullinan Therapeutics (NASDAQ:CGEM) had its price target raised by analysts at HC Wainwright from $24.00 to $26.00. They now have a "buy" rating on the stock.
11/20
07:00 am
cgem
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR E
Low
Report
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR E